• Access To Medicines

Altasciences Expands Ligand Binding Laboratory To Meet High Demand For Bioanalytical Solutions

Altasciences is pleased to announce the completion of a second expansion of our bioanalytical laboratory, which provides a cutting-edge research facility with new state-of-the-art equipment for ligand binding assays, and greater capacity for all our clients' needs.

Quell Therapeutics Significantly Expands Clinical Manufacturing Capacity for its Engineered Treg Cell Therapies through a Collaboration with the Cell and Gene Therapy Catapult

Collaboration to facilitate an expanded manufacturing footprint to enable clinical supply of Quell’s pipeline, including QEL-001 in liver transplantation and pipeline programs in neuroinflammation and autoimmunity.

Dr John Brown, CBE to retire as Cell and Gene Therapy Catapult’s Chairman

John Brown will retire at the end of 2021 after nine years in the role. Dr John Brown, CBE, FRSE, Chairman of Cell and Gene Therapy Catapult (CGT Catapult), will retire from the role at the end of 2021 after completing three successive terms. The Nomination Committee will establish a process, led by Hilary Newiss, to identify and appoint his successor in due course.

AAV reference material to be produced at the Cell and Gene Therapy Catapult Braintree in collaboration with the National Institute for Biological Standards and Control

London, UK, 16th September 2021 – A 6-month collaborative project was announced today that will help to accelerate the introduction of regulated advanced gene therapies that use Adenovirus-associated vectors (AAVs).

Innovative gene therapy programme paves the way for new treatments for neurodegenerative diseases

An innovative gene therapy programme which could pave the way for novel treatments for neurodegenerative diseases, has been launched at the University of Sheffield in collaboration with the Cell and Gene Therapy Catapult.

Cytiva and Pall Corporation invest 1.5 billion USD for capacity expansion

An ongoing strategic growth plan from Cytiva and Pall Corporation, part of the Danaher (NYSE: DHR) Corporation, will expand manufacturing capacity and services across geographies for global life sciences customers. The investment, already underway, includes new sites, expansion at existing factories, and is additional to previously announced investments. It follows five acquisitions made by the companies so far this year.

Medicines Discovery Catapult welcomes new scientific and people leaders

Medicines Discovery Catapult (MDC) is proud to announce an extension to its talented workforce, further expanding the organisation’s expert R&D offer and adding over 80 years of drug discovery and corporate experience to the team.

NovaBiotics Announces Cysteamine Bitartrate (NM002) Included in REMAP-CAP Phase 3 Clinical Trial for Community Acquired Pneumonia

Randomized embedded multi-factorial platform trial to provide accelerated, real-world evidence in community acquired pneumonias including COVID-19, influenzas and bacterial pneumonias

Enterprise Therapeutics doses first subjects in Phase I trial for novel cystic fibrosis therapy ETD001

• ETD001 is a novel inhaled, long-acting ENaC inhibitor • Therapy applicable to all cystic fibrosis patients, independent of genotype

How are companies across the Bruntwood SciTech network improving access to better healthcare, medicines and treatments?

The Bruntwood SciTech network is home to some of the UK’s most pioneering science companies, from small medtech startups and scaleups, all the way through to global life science companies that are uncovering world-leading discoveries, creating new medicines and shaping the future of our healthcare. So who are some of the UK’s most innovative life science businesses at the forefront of helping to create a fairer and healthier world?